Business Context and Reporting Period
Company: Bionano Genomics, Inc. (BNGO)
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2022
Reporting Period: Preliminary results for the fourth quarter of 2021 and the full year ended December 31, 2021.
Key Financial Metrics
This Form 8-K serves as a notification that the Company issued a press release containing preliminary performance results. The specific numerical values for revenue, profit, cash flow, margins, debt, and liquidity are not contained within the text of this filing. The filing states that the detailed results are located in the attached press release (Exhibit 99.1), which is incorporated by reference but not reproduced in this document.
Material Changes
The filing does not provide specific data to compare current period performance against prior comparable periods. Investors must refer to the referenced press release (Exhibit 99.1) for details on material changes in operations or financial condition.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the issuance of a press release regarding preliminary results but does not include the text of the commentary, guidance, or outlook.
Risks and Contingencies: No specific risks or contingencies are detailed in this 8-K text. The filing includes a standard disclaimer that the information contained herein shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability unless expressly incorporated by reference in other filings.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific revenue, net loss, and cash position figures for Q4 and FY 2021.
- Verify the Company's cash runway and burn rate as disclosed in the press release.
- Check for any updated forward-looking guidance or operational milestones mentioned in the press release.
- Confirm the status of the Company's emerging growth company election and any related accounting transitions.